Cargando…

A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis

OBJECTIVE: To prepare a novel nanoemulsion- Carbopol® 934 gel for Eugenol, in order to prevent the periodontitis. MATERIAL AND METHODS: Spontaneous emulsification method was used for the preparation of nanoemulsion in which it contain Eugenol (oil phase), Tween-80 (surfactant), and PEG (co-surfactan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Niyaz, Ahmad, Farhan Jalees, Bedi, Sumit, Sharma, Sonali, Umar, Sadiq, Ansari, Mohammad Azam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733787/
https://www.ncbi.nlm.nih.gov/pubmed/31516320
http://dx.doi.org/10.1016/j.jsps.2019.04.014
_version_ 1783450023483146240
author Ahmad, Niyaz
Ahmad, Farhan Jalees
Bedi, Sumit
Sharma, Sonali
Umar, Sadiq
Ansari, Mohammad Azam
author_facet Ahmad, Niyaz
Ahmad, Farhan Jalees
Bedi, Sumit
Sharma, Sonali
Umar, Sadiq
Ansari, Mohammad Azam
author_sort Ahmad, Niyaz
collection PubMed
description OBJECTIVE: To prepare a novel nanoemulsion- Carbopol® 934 gel for Eugenol, in order to prevent the periodontitis. MATERIAL AND METHODS: Spontaneous emulsification method was used for the preparation of nanoemulsion in which it contain Eugenol (oil phase), Tween-80 (surfactant), and PEG (co-surfactant). To the development of best nanoemulsion, three-factor three-level central composite design was used in which %oil; %S(mix) and % water were optimized as independent variables. An optimized–nanoemulsion were converted to nanoemulsion–Carbopol® 934 gel. RESULTS: 5.5% oil, 35.5% S(mix) and 59.0% water were optimized as independent and dependent variables. Finally dependent variables optimized as a particle size (nm), PDI and %transmittance were observed 79.92 ± 6.33 nm, 0.229 ± 0.019, and 98.88 ± 1.31% respectively. The values of final results for dependent variables like particle size (nm), PDI and % transmittance were evaluated as 79.92 ± 6.33 nm, 0.229 ± 0.019, and 98.88 ± 1.31%, respectively. TEM and SEM showed a spherical shape of developed nanoemulsion with refractive index (1.63 ± 0.038), zeta potential (−19.16 ± 0.11), pH (7.4 ± 0.06), viscosity (34.28 ± 6 cp), and drug content of 98.8 ± 0.09%. After that a final optimized EUG–NE–Gel was assessed on the basis of their pH measurement, drug content, syringeability, and mucoadhesion on the goat buccal mucosa. Optimized EUG-NE-Gel (Tween-80 and Carbopol® 934 used) showed the results, to improve the periodontal drug delivery of EUG in future. CONCLUSION: EUG-NE-Gel showed a significant role in anti-inflammatory activity, analgesic, and anesthetic, antibacterial, and treatment of periodontal disease.
format Online
Article
Text
id pubmed-6733787
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67337872019-09-12 A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis Ahmad, Niyaz Ahmad, Farhan Jalees Bedi, Sumit Sharma, Sonali Umar, Sadiq Ansari, Mohammad Azam Saudi Pharm J Article OBJECTIVE: To prepare a novel nanoemulsion- Carbopol® 934 gel for Eugenol, in order to prevent the periodontitis. MATERIAL AND METHODS: Spontaneous emulsification method was used for the preparation of nanoemulsion in which it contain Eugenol (oil phase), Tween-80 (surfactant), and PEG (co-surfactant). To the development of best nanoemulsion, three-factor three-level central composite design was used in which %oil; %S(mix) and % water were optimized as independent variables. An optimized–nanoemulsion were converted to nanoemulsion–Carbopol® 934 gel. RESULTS: 5.5% oil, 35.5% S(mix) and 59.0% water were optimized as independent and dependent variables. Finally dependent variables optimized as a particle size (nm), PDI and %transmittance were observed 79.92 ± 6.33 nm, 0.229 ± 0.019, and 98.88 ± 1.31% respectively. The values of final results for dependent variables like particle size (nm), PDI and % transmittance were evaluated as 79.92 ± 6.33 nm, 0.229 ± 0.019, and 98.88 ± 1.31%, respectively. TEM and SEM showed a spherical shape of developed nanoemulsion with refractive index (1.63 ± 0.038), zeta potential (−19.16 ± 0.11), pH (7.4 ± 0.06), viscosity (34.28 ± 6 cp), and drug content of 98.8 ± 0.09%. After that a final optimized EUG–NE–Gel was assessed on the basis of their pH measurement, drug content, syringeability, and mucoadhesion on the goat buccal mucosa. Optimized EUG-NE-Gel (Tween-80 and Carbopol® 934 used) showed the results, to improve the periodontal drug delivery of EUG in future. CONCLUSION: EUG-NE-Gel showed a significant role in anti-inflammatory activity, analgesic, and anesthetic, antibacterial, and treatment of periodontal disease. Elsevier 2019-09 2019-04-29 /pmc/articles/PMC6733787/ /pubmed/31516320 http://dx.doi.org/10.1016/j.jsps.2019.04.014 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Ahmad, Niyaz
Ahmad, Farhan Jalees
Bedi, Sumit
Sharma, Sonali
Umar, Sadiq
Ansari, Mohammad Azam
A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis
title A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis
title_full A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis
title_fullStr A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis
title_full_unstemmed A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis
title_short A novel Nanoformulation Development of Eugenol and their treatment in inflammation and periodontitis
title_sort novel nanoformulation development of eugenol and their treatment in inflammation and periodontitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733787/
https://www.ncbi.nlm.nih.gov/pubmed/31516320
http://dx.doi.org/10.1016/j.jsps.2019.04.014
work_keys_str_mv AT ahmadniyaz anovelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT ahmadfarhanjalees anovelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT bedisumit anovelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT sharmasonali anovelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT umarsadiq anovelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT ansarimohammadazam anovelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT ahmadniyaz novelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT ahmadfarhanjalees novelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT bedisumit novelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT sharmasonali novelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT umarsadiq novelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis
AT ansarimohammadazam novelnanoformulationdevelopmentofeugenolandtheirtreatmentininflammationandperiodontitis